Skip to main content
PLOS One logoLink to PLOS One
. 2022 Oct 17;17(10):e0276215. doi: 10.1371/journal.pone.0276215

Identification of suitable reference genes for normalization of reverse transcription quantitative real-time PCR (RT-qPCR) in the fibrotic phase of the bleomycin mouse model of pulmonary fibrosis

Oula Norman 1, Jarkko Koivunen 1, Joni M Mäki 1, Taina Pihlajaniemi 1, Anne Heikkinen 1,*
Editor: Kyung-Wan Baek2
PMCID: PMC9576074  PMID: 36251700

Abstract

Idiopathic pulmonary fibrosis (IPF) is a severe lung disease with a poor prognosis and few treatment options. In the most widely used experimental model for this disease, bleomycin is administered into the lungs of mice, causing a reaction of inflammation and consequent fibrosis that resembles the progression of human IPF. The inflammation and fibrosis together induce changes in gene expression that can be analyzed with reverse transcription quantitative real-time PCR (RT-qPCR), in which accurate normalization with a set of stably expressed reference genes is critical for obtaining reliable results. This work compares ten commonly used candidate reference genes in the late, fibrotic phase of bleomycin-induced pulmonary fibrosis and ranks them from the most to the least stable using NormFinder and geNorm. Sdha, Polr2a and Hprt were identified as the best performing and least variable reference genes when alternating between normal and fibrotic conditions. In order to validate the findings, we investigated the expression of Tnf and Col1a1, representing the hallmarks of inflammation and fibrotic changes, respectively. With the best three genes as references, both were found to be upregulated relative to untreated controls, unlike the situation when analyzed solely with Gapdh, a commonly used reference gene. We therefore recommend Sdha, Polr2a and Hprt as reference genes for RT-qPCR in the 4-week bleomycin challenge that represents the late fibrotic phase.

Introduction

Idiopathic pulmonary fibrosis (IPF) is the most common of the interstitial pneumonias and is a progressive incurable disease with a poor prognosis. Its yearly incidence in Europe and North America is estimated to be 2.8–18 cases per 100 000 persons, which is similar to diseases such as stomach or brain cancer [1]. The cause of the disease has been viewed as being a combination of various genetic and environmental cues that lead to the proliferation of fibroblasts and the accumulation of pathological extracellular matrix, a process in which changes in gene expression are instrumental, ultimately leading to the alveolar space being replaced with connective tissue. Multiple attempts have been, and continue to be, made to develop an anti-fibrotic drug, but despite pre-clinical studies showing positive effects, most compounds have not shown comparable performance in clinical trials [2] and to date only two anti-fibrotic pharmaceuticals that retard the progression of IPF have been approved for use [3]. Thus we still need a better understanding of the disease and more effective therapy, as median survival remains at the level of 2–4 years after diagnosis [1], thereby empowering further investigations.

Reverse transcription quantitative real-time PCR (RT-qPCR) is a widely used method for assessing gene expression, the key to its accuracy being valid normalization of the expression of the gene of interest to a set of stably expressed reference genes in order to minimize the effects of differences in the quantity and quality of the RNA between individual samples. The reference genes are often housekeeping genes that have a role in the cell’s basic vital activities such as energy metabolism or protein synthesis. A systematic review by Chapman and Waldenström [4] shows that the most commonly used reference genes are beta-actin (Actb), glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and the ribosomal RNA 18S subunit (Rn18s), although even their expression does not always remain stable but often varies between experimental groups. Thus the optimal reference genes have to be verified for the experiment in question in order to achieve accurate results. Gapdh, in particular, has numerous pseudogenes that may confound the analysis [5, 6]. In addition, it is upregulated under hypoxic conditions and most inflammatory tissues exhibit a degree of hypoxia due to edema [7]. In the case of Actb attention should be paid to primer design, as it shares 91% of its sequence with leucine-rich repeat-containing 58 (Lrrc58) [6].

Different methods have been developed to determine which genes are most suitable for normalization, some of the most commonly used algorithms being NormFinder [8] and geNorm [9]. NormFinder employs a model-based approach that estimates intra- and intergroup variance for each candidate gene. This approach relies on the assumption that the average expression of the candidate genes will be the same in both experimental groups. geNorm uses a pairwise comparison approach in which the candidate genes are ranked according to the similarity of their expression profiles. This method requires that the candidate genes be regulated independently of each other. Unlike NormFinder, geNorm does not compare the expression levels of the candidate genes between experimental groups but instead comparisons are made between all the samples. RNA sequencing has also been used for finding stably expressed genes, but Sampathkumar et al. [10] recently demonstrated that the results are similar to the conventional approach.

Bleomycin is an anti-neoplastic drug that has a potential to cause lung fibrosis when used in large doses [11]. The histological changes it causes in mouse lungs are relatively similar to those seen in human IPF and thus the bleomycin model is the most widely used experimental animal model for studying pulmonary fibrosis [12]. The reaction to the administration of bleomycin to the lungs consists of an initial phase of acute lung injury, inflammation and the development of fibrosis that lasts for around two weeks, followed by a phase of established fibrosis from two to four weeks after bleomycin administration and ultimately slow resolution of the fibrosis [2]. A previous study has explored suitable reference genes in the initial inflammatory phase of the bleomycin mouse model [13], but to the best of our knowledge there are no reports on reference genes suitable for the normalization of RT-qPCR in the fibrotic phase of the bleomycin model by comparison with the untreated state. We present here data on the expression of ten commonly used reference genes during the fibrotic phase of the bleomycin mouse model and rank them for their utility in normalizing gene expression.

Materials and methods

Ethics approval

Permission for the administration of bleomycin and the induction of fibrosis was obtained from the Finnish Animal Care and Use Committee (ESAVI/8179/04.10.07/2017). All the mouse experiments complied with the European Community Council Directive on the protection of animals used for scientific purposes (September 22, 2010; 2010/63/EEC), national legislation and the regulations for the care and use of laboratory animals.

The bleomycin mouse model of pulmonary fibrosis

The mice used here were part of a larger study on the effect of collagen XIII deficiency on pulmonary fibrosis and were wild-type littermates of collagen XIII (Col13a1) knockout mice of both sexes. The generation of the mice is described in detail by Latvanlehto et al. [14]. The genetic background of the mice originates from sv129 embryonic stem cells followed by cross breeding with the C57BL/6JOlaHsd strain for 17 generations and the C57BL/6NClr strain for 3–4 generations. The mice were maintained in a specific pathogen free (SPF) facility at +21°C with a 12-hour light-dark cycle and were fed Teklad global 18% protein rodent diet with ad libitum access to food and water. From 6 weeks of age onwards the mice were transferred to animal research facilities and the diet was supplemented with banana and hazelnut cocoa spread to minimize malnutrition and mortality during the development of pulmonary fibrosis. 8-week-old mice were anesthetized with isoflurane and given 1,25 U/kg bleomycin (Baxter) diluted with sterile isotonic saline to a volume of 1.67 microliters/g of body weight by oropharyngeal aspiration as described by Barbayianni et al. [15]. Untreated mice served as controls. After 4 weeks of follow-up the mice were sacrificed by injection of fentanyl, midazolam and medetomidine and exsanguination. The left lung was fixed with intratracheal fixation with 4% paraformaldehyde (PFA) at a pressure of 25 cm H2O for 2 minutes to open the airways with the right bronchi ligated to prevent fixation. The right lung lobes were dissected, snap frozen in liquid nitrogen and stored at -80°C. The right postcaval lobe was used for extraction of RNA. After dissection of the right lobes, the left lobe was immersed in 4% PFA for 24 h, embedded in paraffin and used for histological analysis.

Total RNA extraction and cDNA synthesis

Total RNA was isolated from the frozen right postcaval lung lobes using an RNeasy kit (Qiagen) according to the manufacturer’s instructions. All the samples were processed in one batch. The quantity and purity of the RNA were assessed by measuring absorbances at 260 and 280 nm with a Nanodrop spectrophotometer (Thermo Scientific). The quality of the RNA was assessed by capillary electrophoresis using a Bioanalyzer 2100 (Agilent). Based on their fibrotic histological appearance and adequate RNA quality, 9 (4 male, 5 female) bleomycin-treated samples and 10 (5 male, 5 female) untreated samples were selected for use in the analyses. cDNA was synthetized with an iScript cDNA Synthesis kit (Bio-Rad) according to the instructions, using 1000 ng of total RNA and including all the samples in one batch. Genomic DNA was not digested in order to assess whether it affected the results.

Quantitative real-time PCR

The RT-qPCR reactions were performed using 5 μl iTaq Universal SYBR Green Supermix (Bio-Rad), 1.2 μl of forward and reverse primers at 2.5 μM, 2 μl of cDNA template diluted 1:10 and 0.6 μl of water to a final volume of 10 μl. All the reactions were performed in triplicate and those for a given target gene were all performed on the same plate to minimize batch effects. Efficiency analyses were mostly performed separately from the sample analyses. The instrument used was a CFX 96 Real-Time PCR system (Bio-Rad). The thermocycling protocol consisted of 3 minutes at 95°C followed by 40 cycles of denaturation for 15 seconds at 95°C and annealing for 45 seconds. The annealing temperature was 55°C for the primers for the succinate dehydrogenase complex subunit A (Sdha), 64°C for the RNA polymerase II subunit A (Polr2a) and 60°C for all the other targets. Melt curves were created by heating from 55°C to 95°C with 5-second increments of 0.5°C and used to assess the specificity of the PCR.

Primers

The primer sequences were mostly collected from previous publications (Table 1). To minimize unspecific amplification, the primers should be specific to the gene of interest, not form dimers and the amplicon should stretch across an exon-exon junction to distinguish possible genomic DNA amplification. The primer specificity was verified with Primer-BLAST [16]. The primers for Gapdh and peptidylprolyl isomerase A (Ppia) both amplified several pseudogenes according to BLAST, whereas the other primers were specific to the gene of interest. Amplification of a series of four consecutive 1:5 dilutions of cDNA pooled from the samples with three replicates for each dilution was used to generate a standard curve with quantification cycle (Cq) values on the Y-axis and Log10 of the dilution on the X-axis, a line fitted to the points and primer efficiency (E) calculated with the equation: E=101/slopeofstandardcurve [17]. The standard curves for all the primers, were within the linear dynamic range as indicated by R2 of the standard curves, and the Cq values of all the samples fell inside the linear dynamic range.

Table 1. Characteristics of the primers used here.

Gene symbol Biological function Accession number Amplicon length bp Forward primer sequence (5’-3’) Forward primer location Reverse primer sequence (5’-3’) Reverse primer location Efficiency % R2 of standard curve Reference for primer sequence
Actb Cytoskeleton NM_007393.3 110 ACACCCGCCACCAGTTC Exon 1 TACAGCCCGGGGAGCAT Exon 2 92.3 0.999 [6]
B2m Antigen presentation NM_009735.3 200 TGCTACTCGGCGCTTCAGTC Exon 1 AGGCGGGTGGAACTGTGTTAC Exon 2 89.5 0.997 [18]
Col1a1 Connective tissue component NM_007742.4 159 GGGGCAAGACAGTCATCGAA Exon 51 GAGGGAACCAGATTGGGGTG Exon 51 93.1 0.999 [19]
Gapdh Glycolysis NM_001289726.1 104 CATGGCCTTCCGTGTTCCTA Exon 7 CCTGCTTCACCACCTTCTTGAT Exon 7 91.2 0.999 [20]
Gusb Lysosome component NM_010368.2 86 CACGGCGATGGACCCAAGAT Exon 2 CCCATTCACCCACACAACTGC Exon 2–3 87.4 0.990 [21]
Hprt Purine metabolism NM_013556.2 125 CCCAGCGTCGTGATTAGTGATG Exon 1–2 TTCAGTCCTGTCCATAATCAGTC Exon 2–3 92.9 0.993 [13]
Polr2a RNA polymerase NM_001291068.1 144 ATCAACAATCAGCTGCGGCG Exon 6 GCCAGACTTCTGCATGGCAC Exon 7 91.1 0.995 [21]
Ppia Protein folding NM_008907.2 125 GAGCTGTTTGCAGACAAAGTTC Exon 2 CCCTGGCACATGAATCCTGG Exon 3 96.0 0.999 [22]
Rn18s Ribosome component NR_003278.3 123 GCAATTATTCCCCATGAACG N/A GGCCTCACTAAACCATCCAA N/A 94.4 0.998 [23]
Sdha Citric acid cycle NM_023281.1 103 CTCTTTTGGACCTTGTCGTCTTT Exon 9 TCTCCAGCATTTGCCTTAATCGG Exon 10 89.9 0.997 [13]
Tbp Transcription factor NM_013684.3 123 CACCGTGAATCTTGGCTGTAAAC Exon 4 CGCAGTTGTTCGTGGCTCTC Exon 5 86.5 0.993 [13]
Tnf Inflammation NM_013693.3 117 TGCCTATGTCTCAGCCTCTT Exon 1 GAGGCCATTTGGGAACTTCT Exon 2 87.2 0.997 [24]

Histological analysis

After fixation the left lungs were embedded in paraffin in the frontal plane and cut into 5 μm sections at 200 μm intervals. The sections were stained with Masson’s trichrome. One section immediately before the main bronchus and one after were used for histological analysis. The slides were scanned at 40 x magnification with a NanoZoomer S60 slide scanner (Hamamatsu). Regions of interest with only lung tissue in them were drawn with QuPath [25] and the images downsampled by a factor of 5 with a script [26] to enable processing with ImageJ. Ten 0.9 x 0.9 mm fields were randomly sampled from each section using an ImageJ script modified from [27] and graded using the modified Ashcroft scale [28] independently by 2 observers blinded to the treatment. The scores from all the observers for a given field were averaged, after which the scores for all the fields of the sample were averaged to obtain the score for the entire sample.

Data analysis

Bio-Rad CFX Maestro 2.2 software was used to analyze the raw data. Automated functions within the software were used for baseline correction, thresholding and Cq determination. For Fig 3, the raw Cq values were corrected for primer-specific PCR efficiency using the formula Cqcorrected=Cqraw(logElog2). The melt curves were inspected to confirm the specificity of the amplification. NormFinder for R (https://moma.dk/normfinder-software) [8] and GeNorm [9] for Bio-Rad CFX Maestro were used according to their respective instructions. For the NormFinder analysis the raw Cq values were transformed to relative quantities on a linear scale using the formula Relativequantity(Rq)=EΔCq, where ΔCq=Cqsample1Cqsampleofinterest. Expression of the collagen I alpha 1 chain (Col1a1) and tumor necrosis factor (Tnf) normalized to the combination of Sdha, Polr2a and hypoxanthine guanine phosphoribosyl transferase (Hprt1) was calculated using CFX Maestro with the formula: Normalizedexpressionsample(GOI)=Rqsample(GOI)Rqsample(Sdha)*Rqsample(Polr2a)*Rqsample(Hprt)3, where GOI = gene of interest, as proposed by Pfaffl [29] and Vandesompele et al. [9], and expression of Col1a1 and Tnf normalized to Gapdh was calculated using the formula Normalizedexpressionsample(GOI)=Rqsample(GOI)Rqsample(Gapdh).

Fig 3. Efficiency-corrected Cq values for the genes investigated in untreated and bleomycin-treated mice.

Fig 3

Untreated: untreated samples. Bleomycin: bleomycin-treated samples. Each box has lines for minimum, maximum and mean values. X-axis truncated; 40 cycles were run. n = 9–10.

Statistical analyses and software

The Mann-Whitney U test was used to compare distributions between groups. Data were analyzed with GraphPad Prism (GraphPad Software). GraphPad Prism, CorelDRAW 2021 (Corel) and Corel PHOTO-PAINT 2021 (Corel) were used to create the figures.

Results

Level of pulmonary fibrosis

To confirm the suitability of the samples for investigating pulmonary fibrosis, the degree of fibrosis in the lungs was graded with a modified Ashcroft score [28]. The bleomycin-treated samples showed clear fibrotic changes with a mean score of 3.2 (Standard deviation (SD) 0.98), while the untreated mice had a score of 0.4 (SD 0.086) and exhibited no signs of pulmonary fibrosis (Fig 1).

Fig 1. Lung fibrosis at 4 weeks after bleomycin administration.

Fig 1

a) Masson’s trichrome staining of an untreated left lung and b) of a bleomycin-treated left lung. Fibrotic changes are indicated by arrows. Scale bars 1 mm. c) Example of a 0.9 mm wide close-up image of a bleomycin-treated lung produced by the random sampling procedure, with a modified Ashcroft score of 5. A nonlinear tone curve adjustment was applied to all images to correct white balance. d) Modified Ashcroft scores for the experimental groups, untreated (round symbols) and bleomycin-treated (square symbols). Lines at means. n = 9–10. Mann-Whitney U test.

RNA integrity

Given that RNA integrity (RIN) values above 5 are considered sufficient for RT-qPCR analysis [30], the average RIN values recorded here were 6.6 (SD 0.45) for untreated and 6 (SD 0.51) for bleomycin-treated samples (Fig 2). The values were on average 10%, or 0.6 units, lower in the bleomycin-treated group (Fig 2), possibly reflecting different conditions in the fibrotic tissue, since the sample collection and RNA extraction procedures were the same for all the samples. Nevertheless, given the similarity of the values, the samples should be readily comparable.

Fig 2. RNA quality.

Fig 2

RIN values for the untreated (round points) and bleomycin-treated samples (square points). Lines at means. n = 9–10. Mann-Whitney U test. Dashed line at RIN = 5.

Expression characteristics of the candidate genes

The primer efficiency was between 85% and 110% for all the primer pairs, which is considered sufficient for RT-qPCR [30]. This efficiency was taken into account when correcting the Cq values and when calculating the relative quantities. All the primer pairs amplified products that had efficiency-corrected Cq values between 13 and 30 (Fig 3), and each primer pair showed uniform single-peak melting curves for all the samples. No template control (NTC) Cq values were over 38 for all the primers except for Rn18s, for which they were above 30, and for Sdha, for which they were above 33, all indicating sufficiently low background signal levels. No reverse transcription (NRT) controls for Gapdh had a Cq value of 22.13 while the highest Cq for a sample was 21.21 and Ppia had a Cq of 23.90 with the highest Cq for a sample being 22.0. NRT controls for all other genes had Cq values at least 7 cycles higher than the sample with the highest Cq, indicating that the primers did not significantly amplify genomic DNA. The NRT values for Gapdh and Ppia indicate that up to 35% and 22%, respectively, of the expression detected with RT-qPCR could originate from pseudogenes or other unspecific amplification and cause variation in the results. Neither the primers for Gapdh nor those for Col1a1 were exon junction-spanning, but as the NRT control for Col1a1 did not exhibit unspecific amplification from genomic DNA, the unspecific amplification in the NRT control for Gapdh is most likely to have originated from pseudogenes or similar sequences.

Reference gene stability

Normfinder and geNorm for Bio-Rad CFX Maestro algorithms were used to rank the reference genes in terms of their stability, and averages were calculated from these ranks to obtain the overall ranking (Fig 4). Sdha performed best in both analyses, and Ppia, Polr2a and Hprt were the three next best genes, although the potential pseudogene problem of Ppia makes it a suboptimal choice. The most commonly used reference gene, Gapdh, showed the poorest performance according to both programs, and Actb and Rn18s performed less well than most other candidates. Thus we suggest that Sdha, Polr2a and Hprt would form the best combination of reference genes for assessing bleomycin-induced pulmonary fibrosis at the 4-week time point.

Fig 4. Comparison of the stability values of the candidate reference genes.

Fig 4

Values from a) NormFinder and b) geNorm, and c) average of ranks based on the two programs.

Validation of candidate reference genes

In order to validate the findings, the expression levels of Col1a1 and Tnf, which are expected to be increased under fibrotic conditions, were compared between the experimental groups using Sdha, Polr2a and Hprt as the reference genes (Fig 5). The expression of Col1a1 appears to be slightly upregulated in the bleomycin-treated samples and Tnf clearly so, as expected. When only Gapdh was used as a reference gene, however, neither Col1a1 nor Tnf showed any significant differences between the groups.

Fig 5. Validation of selected normalization strategies.

Fig 5

Changes in the expression of Col1a1 (a, c) and Tnf (b, d) in bleomycin-treated mice (square points) relative to untreated mice (round points) when Sdha, Polr2a and Hprt are used as reference genes (a, b) and Gapdh as reference (c, d). Lines at medians. n = 9–10. Mann-Whitney U test.

Discussion

We present here a strategy for determining the optimal reference genes for RT-qPCR normalization in the widely used bleomycin model of pulmonary fibrosis at 4 weeks post-treatment, i.e. the late fibrotic stage. Accurate normalization is the key to obtaining reliable results, and selecting stably expressed reference genes for normalization can help avoid excessive variation in the results. As established in many earlier studies, a single reference gene is rarely enough for reliable results, so that at least three genes should be used after determining the invariability of their expression [9, 31, 32].

The candidate genes we selected include some of the most popular reference genes used in RT-qPCR analyses, genes having various functions in the cell’s basic activities that are integral to its survival, and therefore genes that may be expected to be expressed steadily under different conditions. We picked primer sequences that were found to work well in previously published studies and were careful to select primers that were specific to the gene of interest, especially with Actb. This is because some of the primers used previously, and also some commercially available primers, were predicted to be unspecific and also to amplify Lrrc58, with which Actb shares 91% of its sequence. The primers for Gapdh and Ppia, however, were found to be nonspecific, as seen from their high NRT values, and hence were deemed unreliable and nonoptimal for acting as reference genes. The fact that the NTC for both genes failed to show significant amplification argues against primer dimerization, and thus the amplification may have been derived from pseudogenes. The pseudogene problem attached to Gapdh has been demonstrated earlier [5], but its continued ubiquitous use as a reference gene warranted its inclusion in this study. The results further demonstrate that the use of Gapdh as the sole reference gene is not appropriate without determining the invariability of its expression by comparing it with a few alternatives, although we would rather recommend reference genes that are free of pseudogene issues. As shown in Fig 5, inappropriate normalization could lead to false results. Actb and Rn18s, the other most commonly used reference genes [4], showed poor performance compared with the remaining candidates studied here. The main issue with Rn18s is that the product is rRNA instead of mRNA and thus its expression is governed by different factors from those lying behind the genes of interest [32].

In this study we used two different algorithms to determine the stability of 10 candidate genes in the late fibrotic phase of bleomycin-induced pulmonary fibrosis in mice. Although the two algorithms represent different approaches to calculating reference gene stability, the best-performing genes are the same in both programs, a fact that highlights their stability. A previous study focusing on the initial inflammatory phase in the bleomycin-induced pulmonary fibrosis model found Hprt, Ppia and Sdha to be the most stable reference genes [13], and our results confirmed the very same genes, with the addition of Polr2a, as acting reliably as reference genes in RT-qPCR at a later stage in pulmonary fibrosis. Taken together, we propose that Hprt, Polr2a and Sdha form a reliable set of reference genes for RT-qPCR in the bleomycin model of pulmonary fibrosis.

Supporting information

S1 Table. Data underlying the findings described.

Cq values and plots of standard curves used for determination of primer efficiency, raw Cq values for all samples, efficiency-corrected Cq values and relative quantities, datafile used for NormFinder analysis, and individual values behind the graphs and results.

(XLSX)

Acknowledgments

The authors thank Jaana Peters and Päivi Tuomaala for technical assistance and Oulu Laboratory Animal Center (OULAC) for care of the animals. The work was supported by Biocenter Oulu, Sequencing Center, and the Transgenic and Tissue Phenotyping Core Facility endowed by the University of Oulu, Finland, and Biocenter Finland.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This study was supported by grants from the Sigrid Jusélius Foundation (TP) (https://www.sigridjuselius.fi/en/), the Jane and Aatos Erkko Foundation (TP) (https://jaes.fi/en/) and the Emil Aaltonen Foundation (ON) (https://emilaaltonen.fi/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. The Lancet. 2017;389: 1941–1952. doi: 10.1016/S0140-6736(17)30866-8 [DOI] [PubMed] [Google Scholar]
  • 2.Jenkins RG, Moore BB, Chambers RC, Eickelberg O, Königshoff M, Kolb M, et al. An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2017;56: 667–679. doi: 10.1165/rcmb.2017-0096ST [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, DeLeon J, et al. Idiopathic pulmonary fibrosis: Current and future treatment. Clin Respir J. 2022;16: 84–96. doi: 10.1111/crj.13466 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chapman JR, Waldenström J. With Reference to Reference Genes: A Systematic Review of Endogenous Controls in Gene Expression Studies. PLoS ONE. 2015;10: e0141853. doi: 10.1371/journal.pone.0141853 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Sun Y, Li Y, Luo D, Liao DJ. Pseudogenes as Weaknesses of ACTB (Actb) and GAPDH (Gapdh) Used as Reference Genes in Reverse Transcription and Polymerase Chain Reactions. PLOS ONE. 2012;7: e41659. doi: 10.1371/journal.pone.0041659 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Mehta A, Dobersch S, Dammann RH, Bellusci S, Ilinskaya ON, Braun T, et al. Validation of Tuba1a as Appropriate Internal Control for Normalization of Gene Expression Analysis during Mouse Lung Development. Int J Mol Sci. 2015;16: 4492–4511. doi: 10.3390/ijms16034492 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Graven KK, Yu Q, Pan D, Roncarati JS, Farber HW. Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. Biochim Biophys Acta. 1999;1447: 208–218. doi: 10.1016/s0167-4781(99)00118-9 [DOI] [PubMed] [Google Scholar]
  • 8.Andersen CL, Jensen JL, Ørntoft TF. Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets. Cancer Res. 2004;64: 5245–5250. doi: 10.1158/0008-5472.CAN-04-0496 [DOI] [PubMed] [Google Scholar]
  • 9.Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3: research0034.1. doi: 10.1186/gb-2002-3-7-research0034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Sampathkumar NK, Sundaram VK, Danthi PS, Barakat R, Solomon S, Mondal M, et al. RNA-Seq is not required to determine stable reference genes for qPCR normalization. PLOS Comput Biol. 2022;18: e1009868. doi: 10.1371/journal.pcbi.1009868 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Della Latta V, Cecchettini A, Del Ry S, Morales MA. Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions. Pharmacol Res. 2015;97: 122–130. doi: 10.1016/j.phrs.2015.04.012 [DOI] [PubMed] [Google Scholar]
  • 12.Carrington R, Jordan S, Pitchford SC, Page CP. Use of animal models in IPF research. Pulm Pharmacol Ther. 2018;51: 73–78. doi: 10.1016/j.pupt.2018.07.002 [DOI] [PubMed] [Google Scholar]
  • 13.Della Latta V, Cabiati M, Burchielli S, Frenzilli G, Bernardeschi M, Cecchettini A, et al. Lung inflammation after bleomycin treatment in mice: Selection of an accurate normalization strategy for gene expression analysis in an ex-vivo and in-vitro model. Int J Biochem Cell Biol. 2017;88: 145–154. doi: 10.1016/j.biocel.2017.05.016 [DOI] [PubMed] [Google Scholar]
  • 14.Latvanlehto A, Fox MA, Sormunen R, Tu H, Oikarainen T, Koski A, et al. Muscle-Derived Collagen XIII Regulates Maturation of the Skeletal Neuromuscular Junction. J Neurosci. 2010;30: 12230–12241. doi: 10.1523/JNEUROSCI.5518-09.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Barbayianni I, Ninou I, Tzouvelekis A, Aidinis V. Bleomycin Revisited: A Direct Comparison of the Intratracheal Micro-Spraying and the Oropharyngeal Aspiration Routes of Bleomycin Administration in Mice. Front Med. 2018;5: 269. doi: 10.3389/fmed.2018.00269 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 2012;13: 134. doi: 10.1186/1471-2105-13-134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Rasmussen R. Quantification on the LightCycler. In: Meuer S, Wittwer C, Nakagawara K-I, editors. Rapid Cycle Real-Time PCR. Berlin, Heidelberg: Springer Berlin Heidelberg; 2001. pp. 21–34. doi: 10.1007/978-3-642-59524-0_3 [DOI] [Google Scholar]
  • 18.Han LQ, Yang GY, Zhu HS, Wang YY, Wang LF, Guo YJ, et al. Selection and use of reference genes in mouse mammary glands. Genet Mol Res. 2010;9: 449–456. doi: 10.4238/vol9-1gmr724 [DOI] [PubMed] [Google Scholar]
  • 19.Gong K, Qu B, Wang C, Zhou J, Liao D, Zheng W, et al. Peroxisome Proliferator-Activated Receptor α Facilitates Osteogenic Differentiation in MC3T3-E1 Cells via the Sirtuin 1-Dependent Signaling Pathway. Mol Cells. 2017;40: 393–400. doi: 10.14348/molcells.2017.0018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Dong Y-F, Chen Z-Z, Zhao Z, Yang D-D, Yan H, Ji J, et al. Potential role of microRNA-7 in the anti-neuroinflammation effects of nicorandil in astrocytes induced by oxygen-glucose deprivation. J Neuroinflammation. 2016;13: 60. doi: 10.1186/s12974-016-0527-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.YOKOYAMA T, OMOTEHARA T, HIRANO T, KUBOTA N, YANAI S, HASEGAWA C, et al. Identification of reference genes for quantitative PCR analyses in developing mouse gonads. J Vet Med Sci. 2018;80: 1534–1539. doi: 10.1292/jvms.18-0417 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Petäistö T, Vicente D, Mäkelä KA, Finnilä MA, Miinalainen I, Koivunen J, et al. Lack of collagen XVIII leads to lipodystrophy and perturbs hepatic glucose and lipid homeostasis. J Physiol. 2020;598: 3373–3393. doi: 10.1113/JP279559 [DOI] [PubMed] [Google Scholar]
  • 23.Aikio M, Elamaa H, Vicente D, Izzi V, Kaur I, Seppinen L, et al. Specific collagen XVIII isoforms promote adipose tissue accrual via mechanisms determining adipocyte number and affect fat deposition. Proc Natl Acad Sci. 2014;111: E3043–E3052. doi: 10.1073/pnas.1405879111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hossen MJ, Yang WS, Kim D, Aravinthan A, Kim J-H, Cho JY. Thymoquinone: An IRAK1 inhibitor with in vivo and in vitro anti-inflammatory activities. Sci Rep. 2017;7: 1–12. doi: 10.1038/s41598-016-0028-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7: 16878. doi: 10.1038/s41598-017-17204-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bankhead P. Script of the Day: Extracting image regions to ImageJ. In: Pete’s blog [Internet]. 7 Mar 2018. [cited 29 Mar 2022]. Available: https://petebankhead.github.io/qupath/scripting/2018/03/07/script-extracting-image-regions-to-imagej.html [Google Scholar]
  • 27.Mason D. Random Access MemoROI. In: Post-Acquisition [Internet]. 21 Jun 2018. [cited 29 Mar 2022]. Available: https://postacquisition.wordpress.com/2018/06/21/random-access-memoroi/ [Google Scholar]
  • 28.Hübner R-H, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, et al. Standardized quantification of pulmonary fibrosis in histological samples. BioTechniques. 2008;44: 507–511, 514–517. doi: 10.2144/000112729 [DOI] [PubMed] [Google Scholar]
  • 29.Pfaffl MW. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res. 2001;29: e45. doi: 10.1093/nar/29.9.e45 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Fleige S, Pfaffl MW. RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med. 2006;27: 126–139. doi: 10.1016/j.mam.2005.12.003 [DOI] [PubMed] [Google Scholar]
  • 31.Dheda K, Huggett JF, Chang JS, Kim LU, Bustin SA, Johnson MA, et al. The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Anal Biochem. 2005;344: 141–143. doi: 10.1016/j.ab.2005.05.022 [DOI] [PubMed] [Google Scholar]
  • 32.Kozera B, Rapacz M. Reference genes in real-time PCR. J Appl Genet. 2013;54: 391–406. doi: 10.1007/s13353-013-0173-x [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Kyung-Wan Baek

6 Sep 2022

PONE-D-22-22612Identification of suitable reference genes for normalization of reverse transcription quantitative real-time PCR in the fibrotic phase of the bleomycin mouse model of pulmonary fibrosisPLOS ONE

Dear Dr. Heikkinen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 21 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Kyung-Wan Baek, Ph.D.

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1.  Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf  and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments :

Your manuscript will be considered suitable for publication in PLos ONE if it undergoes appropriate revisions. Please revise the manuscript to reflect the reviewers' comments.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

********** 

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This paper presents proper reference genes for the RT-qPCR in the pulmonary fibrosis mouse model after treatment of the Bleomycin. In the fibrosis mouse model, the reference gene selection is an important and appropriate study for verifying gene expression. If the authors solve the minor issues below, this paper will be published to the PLoS One.

Manuscript Overall: Gene Symbol should be used as an italic, and all capital letters.

Line 2: Please provide abbreviation of reverse transcription quantitative real-time PCR as (RT-qPCR) in title.

Line 17: two separate algorithms → Please present specific names.

Line 85-86: “ab libitum” please provide as italic.

Line 130 Table 1, 5th and 7th columns: please provide direction of primer sequences (5’-3’).

Figure 3 and 5: There may be confusion in sample names. “Untreated” → “Untreated samples”, “Bleomycin” → “Bleomycin-treated samples”. If you lack space, you can use abbreviations. "UC" and "BTS". The difference between the groups according to the shape of each point (round point, square point) should be described in each figure legend.

Reviewer #2: The ms. by Norman et al. presents data regarding a number of genes that could serve as reference genes in the bleomycin mouse model. These are proposed as stable denominators for gene expression assays during development of fibrosis. The results are an incremental advance of interest to a limited number of investigators. The methods appear technically sound and the data might prove to have some utilitarian value.

********** 

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Oct 17;17(10):e0276215. doi: 10.1371/journal.pone.0276215.r002

Author response to Decision Letter 0


29 Sep 2022

We highly appreciate the opportunity to improve our manuscript according to the valuable comments highlighted by the Reviewers. We have done our best to fully respond to the concerns raised by the reviewers.

Reviewer #1: This paper presents proper reference genes for the RT-qPCR in the pulmonary fibrosis mouse model after treatment of the Bleomycin. In the fibrosis mouse model, the reference gene selection is an important and appropriate study for verifying gene expression. If the authors solve the minor issues below, this paper will be published to the PLoS One.

1) Manuscript Overall: Gene Symbol should be used as an italic, and all capital letters.

RESPONSE: In our manuscript we have followed the gene nomenclature used by the National Center for Biotechnology Information (NCBI), see e.g., the gene for mus musculus collagen type I α1 chain (https://www.ncbi.nlm.nih.gov/gene/12842). According to this, mouse genes are written in a way that they start with an uppercase letter and all other letters are given by lowercase letters. This style is used to differentiate rodent genes from human genes, which are written in capital letters. Official gene symbols for mouse genes are provided by the Mouse Genome Informatics at the Jackson laboratory (http://www.informatics.jax.org/mgihome/nomen/gene.shtml#gaas), as follows:

“Guidelines for Nomenclature of Genes, Genetic Markers, Alleles, and Mutations in Mouse and Rat

2.3 Gene Symbols and Names

2.3.1 Gene Symbols

Genes are given short symbols as convenient abbreviations for speaking and writing about the genes.

A gene symbol should:

• be unique within the species and should not match a symbol in another species that is not a homolog.

• be short, normally 3-5 characters, and not more than 10 characters

• use only Roman letters and Arabic numbers

• begin with an uppercase letter (not a number), followed by all lowercase letters / numbers (see exception below)

• not include tissue specificity or molecular weight designations

• include punctuation only in specific special cases (see below)

• ideally have the same initial letter as the initial letter of its gene name to aid in indexing. However, letter order in a gene symbol need not follow word order in the name.

• When a definitive human ortholog exists, gene symbols should agree with human gene symbols when practical.

• Never prepend 'm' (for a mouse gene symbol) or 'r' (for a rat gene symbol) to indicate species.”

Based on this convention, we would like to stay with the original gene symbol nomenclature, if acceptable by the reviewer. All gene names were originally in italic, but we noticed that when submitting, the system converted italic font to not italic in the Abstract and we were not able to correct this. All gene names are (and were originally) in italic in the Word version of the manuscript.

2) Line 2: Please provide abbreviation of reverse transcription quantitative real-time PCR as (RT-qPCR) in title.

RESPONSE: The abbreviation (RT-qPCR) has been added in the title; page 1, line 5.

3) Line 17: two separate algorithms → Please present specific names.

RESPONSE: Names of two separate algorithms are now present in the Abstract, page 2, line 31.

4) Line 85-86: “ab libitum” please provide as italic.

RESPONSE: “ab libitum” is provided as italic, page 5, lines 101-102.

5) Line 130 Table 1, 5th and 7th columns: please provide direction of primer sequences (5’-3’).

RESPONSE: Directions of primer sequences (5’-3’) has been provided on 5th and 7th columns, page 7, Table 1, row 1.

6) Figure 3 and 5: There may be confusion in sample names. “Untreated” → “Untreated samples”, “Bleomycin” → “Bleomycin-treated samples”. If you lack space, you can use abbreviations. "UC" and "BTS". The difference between the groups according to the shape of each point (round point, square point) should be described in each figure legend.

RESPONSE: The requested change “Untreated” → “Untreated samples”, “Bleomycin” → “Bleomycin-treated samples” has been made in the Fig 2 and Fig 5. Fig 3 itself has not been changed but the following explanation; “Untreated: untreated samples. Bleomycin: bleomycin-treated samples” has been added in the Fig 3 legend, page 10, line 219.

The difference between the groups according to the shape of each point; untreated (round symbols) and bleomycin-treated (square symbols) is now described in the Fig 1 (page 9, lines 188-189), 2 (page 9, lines 199-200) and 5 (page 11, lines 242-243) legends.

Reviewer #2: The ms. by Norman et al. presents data regarding a number of genes that could serve as reference genes in the bleomycin mouse model. These are proposed as stable denominators for gene expression assays during development of fibrosis. The results are an incremental advance of interest to a limited number of investigators. The methods appear technically sound and the data might prove to have some utilitarian value.

Decision Letter 1

Kyung-Wan Baek

2 Oct 2022

Identification of suitable reference genes for normalization of reverse transcription quantitative real-time PCR (RT-qPCR) in the fibrotic phase of the bleomycin mouse model of pulmonary fibrosis

PONE-D-22-22612R1

Dear Dr. Heikkinen,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Kyung-Wan Baek, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

It appears that the manuscript has been improved to a level suitable for publication in PLoS ONE. I do not believe that further review is necessary.

Reviewers' comments:

Acceptance letter

Kyung-Wan Baek

7 Oct 2022

PONE-D-22-22612R1

Identification of suitable reference genes for normalization of reverse transcription quantitative real-time PCR (RT-qPCR) in the fibrotic phase of the bleomycin mouse model of pulmonary fibrosis

Dear Dr. Heikkinen:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Kyung-Wan Baek

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Data underlying the findings described.

    Cq values and plots of standard curves used for determination of primer efficiency, raw Cq values for all samples, efficiency-corrected Cq values and relative quantities, datafile used for NormFinder analysis, and individual values behind the graphs and results.

    (XLSX)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES